Know Cancer

forgot password

Double-Blind, Randomized Control Trial To Evaluate the Efficacy of Duct Tape Versus Placebo for the Treatment of Verruca Vulgaris

18 Years
Not Enrolling
Wart, Common Wart, Verruca Vulgaris, Verruca Plantaris, Plantar Wart

Thank you

Trial Information

Double-Blind, Randomized Control Trial To Evaluate the Efficacy of Duct Tape Versus Placebo for the Treatment of Verruca Vulgaris

ABSTRACT (233 word count)

Objective: To evaluate the efficacy of duct tape occlusion therapy for the treatment of
common warts.

Design: A double-blinded, controlled, clinical intervention trial. Setting: Veterans Affairs
Medical Center. Participants: A total of 90 immunocompetent adult volunteers with at least
one wart measuring between 2-15 mm were enrolled in this study between October 2004 and July
2005; 80 patients completed the study.

Intervention: Patients were randomized using a computer-generated code to receive either
pads consisting of moleskin with transparent duct tape (active) or moleskin alone (control).
Patients were instructed to wear the pads for 7 consecutive days and leave the pad off on
the 7th evening. This process was repeated for 2 months or until the wart resolved,
whichever occurred first. Follow-up visits occurred at 1 and 2 months.

Main Outcome Measure: 100% resolution of the wart. Secondary outcomes included change in
size of the target wart and recurrence rates at 6 months for warts with complete resolution.

Results: There were no statistically significant differences in the proportions of patients
with resolution of the target wart (duct tape=8/39, 21% vs. control=9/41, 22%). Of patients
with complete resolution, 75% (6/8) in the duct tape group and 33% (3/9) of those in the
control group had recurrence of the target wart by the sixth month.

Conclusions: Occlusive therapy with transparent duct tape is not significantly better than
moleskin alone for treatment of common warts in adults.

Inclusion Criteria:

1) ability to comprehend and provide informed consent; 2) age greater
than 18 years old; and 3) at least one common wart, measuring 2-15 millimeters in

Exclusion Criteria: 1) pregnant or lactating females; 2) treatment of the target wart
within the past four weeks by any modality; 3) immunodeficiency state (cancer
chemotherapy, systemic steroids, genetic immunodeficiency, transplant status, etc.); 4)
genital wart only; 5) a history of hypersensitivity or allergy to adhesive tape; 6)
documented allergy to latex; and/or 7) participation in another interventional study or
use of any investigational drug within 30 days prior to enrollment.


Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Outcome Measure:

100% resolution of target wart

Principal Investigator

Erin M. Warshaw, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Minneapolis Veterans Affairs Medical Center


United States: Federal Government

Study ID:




Start Date:

October 2004

Completion Date:

December 2005

Related Keywords:

  • Wart
  • Common Wart
  • Verruca Vulgaris
  • Verruca Plantaris
  • Plantar Wart
  • wart
  • common wart
  • verruca vulgaris
  • verruca plantaris
  • plantar wart
  • duct tape
  • occlusion therapy
  • Warts
  • Foot Diseases



Minneapolis Veterans Affairs Medical Center Minneapolis, Minnesota  55417